ROBOSENSE
7.2.2020 15:02:12 CET | Business Wire | Press release
RoboSense, a leading automotive LiDAR manufacturer, announced today that it has obtained the IATF 16949 certificate in the automotive field, which now fully qualifies it to supply to automotive customers. RoboSense’s LiDAR production line obtained the IATF 16949 Letter of Conformity in December, which has accelerated partnerships of automotive-grade LiDAR serial productions with major OEMs and Tier 1s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200207005157/en/
Developed by the IATF (International Automotive Task Force) and submitted to the International Organization for Standardization (ISO) for approval and publication, IATF 16949 is the most widely used global quality management standard for the automotive industry. In addition, the high quality management that IATF 16949 offers utilizes 5 tools (APQP/FMEA/MSA/SPC/PPAP) as part of their application assessment.
Dr. LeiLei Shinohara, the Co-partner and Vice President of RoboSense, said, "IATF16949 requires extremely high production consistency, and emphasizes various product reliability metrics. It recognizes the RoboSense design, research and development, and production processes. It also indicates that RoboSense has achieved a new milestone of complete readiness for serial mass production of automotive LiDARs, including the latest solid-state smart LiDAR "RS-LiDAR-M1".”
RoboSense's "125-layer equivalent" solid-state LiDAR "RS-LiDAR-M1" was officially released in January 2020 as the world’s first MEMS LiDAR to obtain IATF6949 for its production line. Its production was carried out under the IATF16949 quality management system.
The product development of "RS-LiDAR-M1" followed the APQP and A-SPICE as the basis for the project management and product development process. During production, RoboSense fully implemented the IATF16949 quality management system and ISO26262 functional safety standards. By combining ISO16750 test requirement and other automotive-grade reliability specifications with these systems, the accuracy of the RS-LiDAR-M1 product can be verified.
MEMS mirror is the core component in RS-LiDAR-M1. According to the AEC-Q100 standard, combining the characteristics of MEMS micro-mirror, a total of ten verification test groups were designed, covering factors such as: temperature, humidity, packaging process, electromagnetic compatibility, mechanical vibration and shock, and aging. The cumulative test time for all test samples has now exceeded 100,000 hours. Furthermore, the longest-running prototype has been tested for more than 300 days, while the total road test mileage has exceeded 150,000 kilometers with no degradation found in various testing scenarios.
In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the required standards and the final mass-produced RS-LiDAR-M1 will adapt to all climate and working conditions.
RoboSense continues to optimize the LiDAR performance in order to lead the way towards a driverless future. On September 25, 2019, RoboSense partnered with First Automobile Works (FAW), the world's leading automotive OEM, to include RS-LiDAR-M1 as a core component in FAW's proprietary next-generation autonomous driving system development. On January 8, 2020, during CES2020, RoboSense cooperated with Freetech, the leading ADAS solution provider, on the serial production of the smart multi-sensor fusion solution.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems. By incorporating LiDAR sensors, AI algorithms and IC chipsets, conventional 3D LiDAR sensors are transformed to full data analysis and comprehension systems. The company's mission is to provide outstanding hardware and artificial intelligence capabilities to deliver smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
About IATF
IATF members include BMW Group, Daimler AG, FCA, Ford Motor Company, General Motors Company, Jaguar Land Rover (JLR) Limited, PSA Group, Renault, Volkswagen AG and the vehicle manufacturers respective trade associations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005157/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom